We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Inovio and GeneOne Life Science’s MERS vaccine, which is receiving financial support from the International Vaccine Institute (IVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), elicited high levels of antibodies and T-cell responses in
Inovio and GeneOne Life Science’s MERS vaccine, which is receiving financial support from the International Vaccine Institute (IVI) and the Coalition for Epidemic Preparedness Innovations (CEPI), elicited high levels of antibodies and T-cell responses in
The International Vaccine Institute, with a $34 million grant from the Samsung Foundation to support development in the field, is fully funding the Inovio-GeneOne Korean trial.